[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Glucokinase - Pipeline Review, H2 2019

December 2019 | 60 pages | ID: G9017D069AD2EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Glucokinase - Pipeline Review, H2 2019

SUMMARY

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Diabetes, Obesity and Type 1 Diabetes (Juvenile Diabetes).

The latest report Glucokinase - Pipeline Review, H2 2019, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
  • The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
Eli Lilly and Co
Hua Medicine Shanghai Ltd
Ligand Pharmaceuticals Inc
Merck & Co Inc
Pfizer Inc
Sanwa Kagaku Kenkyusho Co Ltd
Teijin Pharma Ltd
vTv Therapeutics Inc
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles
dorzagliatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2608204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04937319 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMG-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTP-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones
Featured News & Press Releases
Nov 25, 2019: Hua Medicine’s global first-in-class drug was presented at 2019 Scientific Meeting of CDS
Nov 11, 2019: Hua Medicine’s pivotal phase III monotherapy trial of dorzagliatin, a dual-acting glucokinase modulator, achieves primary efficacy endpoint in patients with type 2 diabetes
Nov 08, 2019: Hua Medicine to release phase III 24-weeks topline data of Dorzagliatin monotherapy trial (HMM0301) on November 12
Oct 03, 2019: vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
Sep 18, 2019: vTv Therapeutics presents additional positive data from the phase 2 Simplici-T1 study in patients with type 1 diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
Aug 30, 2019: Hua Medicine completes patient enrollment for Phase III combination with metformin trial of dorzagliatin
Jun 06, 2019: vTv Therapeutics announces positive topline results from part 1 of the Phase 2 Simplici-T1 trial in patients with Type 1 Diabetes
Jun 04, 2019: Hua Medicine - Business & Pipeline Update
Apr 23, 2019: Hua Medicine initiates first combination study of Dorzagliatin with SGLT-2 in the United States
Mar 01, 2019: Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin
Jan 31, 2019: Hua Medicine initiates first combination study of Dorzagliatin with a DPP-4 inhibitor in the United States
Jan 16, 2019: vTv Therapeutics announces publication of comprehensive data in Science Translational Medicine detailing the discovery and clinical development of TTP399, including results of phase 2 AGATA study
Jun 22, 2018: vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
Mar 22, 2018: vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Nov 08, 2017: vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Hua Medicine Shanghai Ltd, H2 2019
Pipeline by Ligand Pharmaceuticals Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019
Pipeline by Teijin Pharma Ltd, H2 2019
Pipeline by vTv Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Eli Lilly and Co
Hua Medicine Shanghai Ltd
Ligand Pharmaceuticals Inc
Merck & Co Inc
Pfizer Inc
Sanwa Kagaku Kenkyusho Co Ltd
Teijin Pharma Ltd
vTv Therapeutics Inc


More Publications